BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price boosted by Royal Bank of Canada to $16.00 in a research note released on Tuesday morning, The Fly reports. The brokerage currently has a positive rating on the biotechnology company’s stock.
A number of other research firms also recently weighed in on BCRX. BidaskClub raised BioCryst Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Friday, November 23rd. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, November 7th. JMP Securities upped their price target on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an outperform rating in a research report on Wednesday, September 5th. Piper Jaffray Companies began coverage on BioCryst Pharmaceuticals in a research report on Friday, November 16th. They set an overweight rating and a $15.00 price target for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $11.41.
NASDAQ:BCRX opened at $8.78 on Tuesday. BioCryst Pharmaceuticals has a twelve month low of $4.25 and a twelve month high of $9.70. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.00 and a quick ratio of 1.98.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. The firm had revenue of $1.45 million for the quarter, compared to analyst estimates of $2.53 million. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.99 EPS for the current fiscal year.
In other news, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the completion of the sale, the insider now owns 140,633 shares of the company’s stock, valued at approximately $1,018,182.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Alane P. Barnes sold 44,290 shares of the stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $9.07, for a total value of $401,710.30. The disclosure for this sale can be found here. In the last three months, insiders sold 135,562 shares of company stock valued at $1,164,765. 4.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in shares of BioCryst Pharmaceuticals by 45.0% in the 2nd quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock valued at $63,581,000 after buying an additional 3,441,498 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the 2nd quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock valued at $6,960,000 after buying an additional 25,685 shares during the last quarter. Spark Investment Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $344,000. Bank of America Corp DE boosted its holdings in shares of BioCryst Pharmaceuticals by 114.2% in the 2nd quarter. Bank of America Corp DE now owns 116,231 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 61,960 shares during the last quarter. Finally, State of Wisconsin Investment Board boosted its holdings in shares of BioCryst Pharmaceuticals by 79.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 44,300 shares during the last quarter. 91.34% of the stock is owned by institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Article: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.